Vor Biopharma (NASDAQ:VOR) Upgraded by Robert W. Baird to “Outperform” Rating

Robert W. Baird upgraded shares of Vor Biopharma (NASDAQ:VOR) from a neutral rating to an outperform rating in a report published on Wednesday morning, Marketbeat reports. The firm currently has $64.00 target price on the stock, up from their prior target price of $20.00.

VOR has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Wednesday, September 24th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Vor Biopharma in a report on Thursday, August 14th. Wall Street Zen cut shares of Vor Biopharma to a “strong sell” rating in a report on Saturday, June 28th. Finally, Zacks Research cut shares of Vor Biopharma from a “hold” rating to a “strong sell” rating in a report on Monday. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $77.83.

Vor Biopharma Trading Down 1.9%

Shares of Vor Biopharma stock opened at $30.22 on Wednesday. Vor Biopharma has a 1 year low of $2.62 and a 1 year high of $65.80. The business’s 50-day simple moving average is $37.05. The company has a market cap of $207.13 million, a PE ratio of -0.11 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Insider Buying and Selling at Vor Biopharma

In other news, major shareholder Reprogrammed Interchange Llc sold 33,668 shares of the firm’s stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $30.32, for a total value of $1,020,813.76. Following the sale, the insider directly owned 1,278,118 shares in the company, valued at approximately $38,752,537.76. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 1,117,860 shares of company stock valued at $24,894,078. 0.45% of the stock is currently owned by company insiders.

Institutional Trading of Vor Biopharma

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new stake in Vor Biopharma in the 2nd quarter worth approximately $66,000. Money Concepts Capital Corp boosted its stake in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after purchasing an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Vor Biopharma in the 1st quarter worth approximately $100,000. Finally, Jane Street Group LLC acquired a new stake in Vor Biopharma in the 1st quarter worth approximately $140,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.